JP7430719B2 - イブジラストを用いて眼疾患／障害または損傷を治療する方法 - Google Patents

イブジラストを用いて眼疾患／障害または損傷を治療する方法 Download PDF

Info

Publication number
JP7430719B2
JP7430719B2 JP2021521130A JP2021521130A JP7430719B2 JP 7430719 B2 JP7430719 B2 JP 7430719B2 JP 2021521130 A JP2021521130 A JP 2021521130A JP 2021521130 A JP2021521130 A JP 2021521130A JP 7430719 B2 JP7430719 B2 JP 7430719B2
Authority
JP
Japan
Prior art keywords
day
ibudilast
pharmaceutically acceptable
acceptable salt
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505184A5 (https=
JP2022505184A (ja
Inventor
和子 松田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of JP2022505184A publication Critical patent/JP2022505184A/ja
Publication of JP2022505184A5 publication Critical patent/JP2022505184A5/ja
Application granted granted Critical
Publication of JP7430719B2 publication Critical patent/JP7430719B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021521130A 2018-10-19 2019-10-18 イブジラストを用いて眼疾患／障害または損傷を治療する方法 Active JP7430719B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748148P 2018-10-19 2018-10-19
US62/748,148 2018-10-19
PCT/US2019/056948 WO2020081941A1 (en) 2018-10-19 2019-10-18 Methods of treating ophthalmic disease/disorder or injury with ibudilast

Publications (3)

Publication Number Publication Date
JP2022505184A JP2022505184A (ja) 2022-01-14
JP2022505184A5 JP2022505184A5 (https=) 2022-10-11
JP7430719B2 true JP7430719B2 (ja) 2024-02-13

Family

ID=68503211

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521130A Active JP7430719B2 (ja) 2018-10-19 2019-10-18 イブジラストを用いて眼疾患／障害または損傷を治療する方法

Country Status (7)

Country Link
US (1) US11154540B2 (https=)
EP (1) EP3866788B1 (https=)
JP (1) JP7430719B2 (https=)
CN (1) CN112804999B (https=)
CA (1) CA3116577A1 (https=)
ES (1) ES2970996T3 (https=)
WO (1) WO2020081941A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010533193A (ja) 2007-07-11 2010-10-21 メディシノバ，インコーポレーテッド イブジラストを含む進行性神経変性疾患の処置用医薬組成物
JP2017535569A (ja) 2014-11-26 2017-11-30 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． イブジラスト及びリルゾールの併用及びその使用法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395747B1 (en) 1998-08-10 2002-05-28 Sauro Sakoda Remedies for multiple sclerosis
JP4954085B2 (ja) 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
JP2009514969A (ja) * 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
WO2008119500A1 (en) * 2007-03-30 2008-10-09 Fovea Pharmaceuticals Sa Methods for treating neovascular ocular diseases
IN2014MN01552A (https=) * 2012-02-27 2015-05-08 Rohto Pharma
TW201406707A (zh) * 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010533193A (ja) 2007-07-11 2010-10-21 メディシノバ，インコーポレーテッド イブジラストを含む進行性神経変性疾患の処置用医薬組成物
JP2017535569A (ja) 2014-11-26 2017-11-30 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． イブジラスト及びリルゾールの併用及びその使用法

Also Published As

Publication number Publication date
CA3116577A1 (en) 2020-04-23
EP3866788A1 (en) 2021-08-25
US11154540B2 (en) 2021-10-26
WO2020081941A1 (en) 2020-04-23
CN112804999A (zh) 2021-05-14
ES2970996T3 (es) 2024-06-03
JP2022505184A (ja) 2022-01-14
CN112804999B (zh) 2024-03-15
EP3866788B1 (en) 2023-12-13
US20200121659A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
US11944607B2 (en) Treatment of progressive neurodegenerative disease with ibudilast
JP7430719B2 (ja) イブジラストを用いて眼疾患／障害または損傷を治療する方法
EP4404928A1 (en) Ibudilast in combination therapy for use in the treatment of glioblastoma
US10946071B2 (en) Combination of ibudilast and interferon-beta and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240131

R150 Certificate of patent or registration of utility model

Ref document number: 7430719

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150